Corrigendum to "Development of N-2,4-pyrimidine-N-phenyl-N′-phenyl ureas as inhibitors of tumor necrosis factor alpha (TNF-α) synthesis. Part 1" [Bioorg. Med. Chem. Lett. 16 (2006) 3510-3513] (DOI:10.1016/j.bmcl.2006.03.095);Development of N-2,4-pyrimidine-N-phenyl-N′-phenyl ureas as inhibitors of tumor necrosis factor alpha (TNF-α) synthesis. Part 1

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 13, 2006, Pages 3510-3513

  Brugel, Todd A ^a   Maier, Jennifer A ^a   Clark, Michael P ^a   Sabat, Mark ^a   Golebiowski, Adam ^a   Bookland, Roger G ^a   Laufersweiler, Matthew J ^a   Laughlin, Steven K ^a   VanRens, John C ^a   De, Biswanath ^a   Hsieh, Lily C ^a   Mekel, Marlene J ^a   Janusz, Michael J ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Cytokine synthesis inhibitors; p38 kinase; Urea

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADENOSINE TRIPHOSPHATE; CARBANILAMIDE DERIVATIVE; HYDROGEN; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; N 2,4 PYRIMIDINE N PHENYL N' PHENYL UREA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CRYSTALLIZATION; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG INTERACTION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HYDROGEN BOND; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; X RAY CRYSTALLOGRAPHY;

EID: 33646823124     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.06.013     Document Type: Erratum

References (16)

1. For a recent review, see:. Adams J.L., Badger A.M., Kumar S., and Lee J.C. In: King F.D., and Oxford A.W. (Eds). Progress in Medicinal Chemistry Vol. 39 (2001), Elsevier, Amsterdam 1-60
2. Bolós J. Mini-Rev. Med. Chem. 5 (2005) 857
3. Badger A.M., Bradbeer J.N., Votta B., Lee J.C., Adams J.L., and Griswold D.E. J. Pharmacol. Exp. Ther. 279 (1996) 1453
4. Boehm J.C., and Adams J.L. Expert Opin. Ther. Patents 10 (2000) 25
5. Goldstein D.M., and Gabriel T. Curr. Top. Med. Chem. 5 (2005) 1017
6. Pargellis C.A., Tong L., Churchill L., Cirillo P., Gilmore T., Graham A.G., Grob P.M., Hickey E.R., Moss N., Pav S., and Regan J. Nat. Struct. Biol. 9 (2002) 268
7. Lee M.R., and Dominguez C. Curr. Med. Chem. 12 (2005) 2979
8. Clark, M. P.; Laughlin, S. K.; Laufersweiler, M. J.; Bookland, R. G.; Brugel, T. A.; Golebiowski, A.; Sabat, M.; Townes, J. A.; VanRens, J. C.; Djung, J. F.; Natchus, M. G.; De, B.; Hsieh, L. C.; Xu, S. C.; Walter, R. L.; Mekel, M. J.; Heitmeyer, S. A.; Brown, K. K.; Juergens, K.; Taiwo, Y. O.; Janusz, M. J. 2004, 47, 2724.
9. 1H NMR, HRMS, and HPLC analysis. Purity was assessed as >95%.
10. 12 (Promega Co., Madison, WI).
11. Mohler K.M., Sleath P.R., Fitzner J.N., Cerretti D.P., Alderson M., Kerwar S.S., Torrance D.S., Otten-Evans C., Greenstreet T., Weerawarna K., Kronhelm S.R., Petersen M., Gerhart M., Kozlosky C.J., March C.J., and Black R.A. Nature 370 (1994) 218
12. Barltrop J.A., Owen T.C., Cory A.H., and Cory J.G. Bioorg. Med. Chem. Lett. 1 (1991) 611
13. 16 Crystals typically diffracted to 1.9 Å resolution and were of the previously reported space group: P212121; a = 65.2 Å, b = 74.6 Å, c = 78.1 Å (4′).
14. Han J., Lee J.D., Bibbs L., and Ulevitch R.J. Science 265 (1994) 808
15. Wang Z., Harkins P.C., Ulevitch R.J., Han J., Cobb M.H., and Goldsmith E.J. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 2327
16. Pav S., Whit D.M., Rogers S., Crane K.M., Cywin C.L., Davidson W., Hopkins J., Brown M.L., Pargellis C.A., and Tong L. Protein Sci. 6 (1997) 242